Shanghai Gynecologic Oncology Group
15
3
6
3
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.0%
0 terminated/withdrawn out of 15 trials
100.0%
+13.5% vs industry average
20%
3 trials in Phase 3/4
0%
0 of 3 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (15)
Artificial Intelligence - Assisted Model for Optimal Timing of Surgery in Advanced Ovarian Cancer
Role: lead
Survival Effect of Hepato-celiac Lymphadenectomy In Primary or Relapsed Ovarian Cancer
Role: lead
Surgery for Relapsed Ovarian Cancer in Precision
Role: lead
O-RADS MRI System on Early Detection of Ovarian Cancer
Role: lead
SCT-001 CAR T Cells Therapy for Relapsed and Refractory Ovarian Cancer
Role: lead
PARPi and Ovarian Cancer Survival
Role: lead
Study of Upfront Surgery Versus Neoadjuvant Chemotherapy in Patients With Advanced Ovarian Cancer (SUNNY)
Role: lead
Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer
Role: lead
Surgery and Niraparib in Secondary Recurrent Ovarian Cancer (SOC-3 Trial)
Role: lead
Study Comparing Tumor Debulking Surgery Versus Chemotherapy Alone in Recurrent Platinum-Sensitive Ovarian Cancer
Role: collaborator
Surgery or Chemotherapy in Recurrent Ovarian Cancer (SOC 1 Trial)?
Role: lead
Stratified Evaluation of PDS and NACT-IDS in Ovarian Cancer (FOCUS)
Role: lead
First-line Intraperitoneal Cisplatin and Etoposide Chemotherapy for Ovarian Cancer
Role: lead
Complete Nerve-Sparing Radical Hysterectomy for Cervical Cancer
Role: lead
Total/Subtotal Colectomy in Ovarian Cancer
Role: lead
All 15 trials loaded